NCT02519335View on ClinicalTrials.gov

Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation

PHASE1TerminatedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions

Heart Defects, Congenital

Interventions

DRUG

Dexrazoxane

Dose escalation every 4 subjects from 200mg/m2/dose; 300mg/m2/dose to 400mg/m2/dose

Trial Locations (1)

75230

Medical City Children's Hospital, Dallas

Sponsors

Collaborators (1)

Mylan Pharmaceuticals Inc

All Listed Sponsors

collaborator

Mylan Pharmaceuticals Inc

INDUSTRY

lead

Medical City Children's Hospital

OTHER